ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
ARA-290 is being researched for tendon applications. Selectively activates the innate repair receptor (IRR), a CD131/EPOR heterodimer, triggering anti-inflammatory and tissue-protective signaling without any effect on red blood cell production. Suppress. Common dosages for this use range from 2-4 mg daily once daily.
Can ARA-290 Help With Tendon?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is being researched for tendon applications based on its mechanism as a Innate repair receptor agonist, anti-inflammatory peptide.
Selectively activates the innate repair receptor (IRR), a CD131/EPOR heterodimer, triggering anti-inflammatory and tissue-protective signaling without any effect on red blood cell production. Suppresses microglia activation and pro-inflammatory cytokine release. Dose-dependently reduces neuropathic pain through central inflammation suppression.
What Does the Research Show for ARA-290 and Tendon?
Clinical trials in sarcoidosis-associated small fiber neuropathy and type 2 diabetes showed significant pain reduction and nerve regeneration. A 28-day protocol initiated measurable corneal nerve fiber regrowth. Chronic stress studies showed antidepressant effects comparable to fluoxetine. 4+ completed clinical trials in humans.
The relevance to tendon specifically comes from ARA-290's effects on neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What Protocol Is Used for Tendon?
For tendon applications, the standard ARA-290 protocol is 2-4 mg daily administered once daily via subcutaneous injection for 28 days typical; 8-16 weeks for extended response.
Some researchers adjust dosing based on the specific tendon application — see our ARA-290 dosage guide for full protocol details.
Can Stacking Improve Tendon Results?
Synergizes with BPC-157 for comprehensive tissue repair — ARA-290 handles neuropathic and inflammatory pathways while BPC-157 targets connective tissue and gut healing.
What Side Effects Apply to Tendon Use?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Side effects are generally consistent regardless of the specific application. See our ARA-290 side effects guide for details.
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →Bottom Line: ARA-290 for Tendon
ARA-290 shows preliminary research potential for tendon. Standard protocols (2-4 mg daily, once daily, 28 days typical; 8-16 weeks for extended response) apply.
Source from COA-tested vendors and maintain consistent dosing for the full cycle duration.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Stacking Guide
- ARA-290 Cycle Guide
- ARA-290 Research
Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.